INVESTORS
Market Opportunity
The pharmaceutical market has relied on the same analytical technology for the past 35-40 years. The processes are integral to all stages of a drug's life cycle, from early research and development in the discovery phase through clinical trials and process R&D, all the way to production.
The pain from this aging process comes from its complexity. It takes multiple scientists, utilizing five to six highly complex instruments, more than 40 different consumables, and over 24 hours to generate actionable data. It sometimes takes between one and two weeks for smaller Pharma to outsource testing.
Novilytic has solved that issue with its patented Proteometer consumable kits. This patented BioTool enables a single scientist to obtain the necessary data in just 10 minutes using a single instrument already part of their workflow and one consumable. In summary, we are "Simplifying BioPharma Analysis."
The opportunity for Novilytic and its investors is substantial. Big Pharma spends more than $2 billion each year on the consumables in this complex analysis of protein-based drugs (i.e., "large molecule"). Our multi-patented technologies enable these scientists to replace all those consumables with the simple Proteometer kit and, using their own instruments, gain data within minutes.
Market and Commercialization Strategy
Our marketing strategy prioritizes addressing the most significant and immediate need first. That concentration is in the late Discovery, Clone Selection, and Process R&D steps of medicinal development. This department also conducts the highest volume of testing, running millions annually.
The tactical efforts of our marketing strategy will focus on top-down and bottom-up calls to action related to new efficiencies and the simple elegance of the Proteometer. Next, we will emphasize its “plug and play” nature and the use of the customer's existing tools, software, and workflows.
The go-to-market strategy will rely on teams of business development specialists paired with technical product managers. This aligns with market expectations and enhances our attractiveness to potential suitors.
All manufacturing will be completed at QMOS and ISO-validated suppliers to complement our similar assembly strategy. Combined, this focus will ensure robust profits and expeditious market expansion.
Technical and Competitive Advantage
The Proteometer is a platform that utilizes nanoparticles and other small molecular ligands with affinity for specific structural components of proteins. The first three versions of our platform address the top market needs. In response to market demand, we will release the next three versions over the next six to nine months, arriving in Q1 and Q2 of 2026. We will then continue to expand into new markets, including animal analytics, mNRA, DNA, and food-based protein markets.
Our patented nanotechnology is exclusively available through us. To ensure ease of use, the Proteometer has been tested and approved for use by four of the top five global instrument companies. Additionally, its effectiveness was validated by pilots at numerous leading pharmaceutical companies. Subsequently, several of them then published peer-reviewed articles and presentations highlighting the Proteometer’s effectiveness and how it has streamlined their organizations.
Artificial Intelligence Opportunities
The Proteometer yields significant data essential to our target market. It plugs into the customer’s existing instruments that have their proprietary AI or push the data to other approved AI used by scientists. Our strategic advantage is that we provide only the data the customer is looking for, without the large amount of miscellaneous (useless) information. This ensures pharmaceutical scientists do not fall into the "garbage in, garbage out" conundrum they currently experience. A significant benefit is that pharmaceutical companies do not have to spend years learning, testing, and security-checking new software. They use what they already have, albeit with much more actionable data.
Regulatory Strategy and Intellectual Property
Using the Proteometer does NOT require approval from the FDA or any other regulatory body, foreign or domestic. It is first being adopted in Pharmaceutical Discovery, Clone Selection, and Process R&D departments without regulatory restrictions. If utilized in manufacturing, it will be included in the pharmaceutical company's FDA submittal. As more than 90 percent of its target users are outside of manufacturing, regulatory approval is not a significant part of our IP Go-to-Market strategy. Our IP includes multiple methods and concept of matter patents, which combine to create a protective mote from outside duplication. We currently have additional patents pending with similar strategies.